The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Authors
Keywords
-
Journal
MEDICAL ONCOLOGY
Volume 37, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-11
DOI
10.1007/s12032-019-1329-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients
- (2019) Véronique Quillien et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
- (2018) Lívia Rojkó et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EG FR -Mutant Lung Adenocarcinoma
- (2018) Po-Hao Feng et al. Journal of Thoracic Oncology
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
- (2018) Linda M. Liau et al. Journal of Translational Medicine
- Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
- (2018) Hayriye Tatli Dogan et al. Diagnostic Pathology
- Dual role of macrophage in tumor immunity
- (2018) Ryota Tamura et al. Immunotherapy
- Glioblastoma Treatments: An Account of Recent Industrial Developments
- (2018) Edouard Alphandéry Frontiers in Pharmacology
- Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
- (2018) Ryota Tamura et al. CANCER SCIENCE
- Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer
- (2018) Yun Liang et al. Diagnostic Pathology
- Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer
- (2018) Hyun-Soo Kim et al. GYNECOLOGIC ONCOLOGY
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
- (2018) Yasuko Tada et al. Journal for ImmunoTherapy of Cancer
- Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome
- (2017) Tsubasa Miyazaki et al. JOURNAL OF NEURO-ONCOLOGY
- Immune microenvironment of gliomas
- (2017) Anna Gieryng et al. LABORATORY INVESTIGATION
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Correlation of immune phenotype with IDH mutation in diffuse glioma
- (2017) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
- (2017) B A Castro et al. ONCOGENE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane
- (2017) Ravi Kumar et al. PLoS One
- The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
- (2017) Song Xue et al. Scientific Reports
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma
- (2016) Alissa A. Thomas et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion
- (2016) Stephanie Du Four et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
- (2016) Yasuharu Akasaki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy
- (2016) Hideyuki Takahashi et al. CANCER SCIENCE
- CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
- (2016) Vinit Kumar et al. IMMUNITY
- Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer
- (2016) Filippos Koinis et al. Journal of Thoracic Oncology
- Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
- (2016) Emma Eriksson et al. Journal of Translational Medicine
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
- (2016) Sarah T. Garber et al. NEURO-ONCOLOGY
- Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion
- (2016) Balint Otvos et al. STEM CELLS
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1.
- (2015) Gordana Vlahovic et al. NEURO-ONCOLOGY
- The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- (2015) S.-J. Shin et al. ONCOLOGIST
- Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer
- (2015) Feifei Teng et al. Translational Research
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- CD8+ and FOXP3+ Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer
- (2014) Eiji Shinto et al. ANNALS OF SURGICAL ONCOLOGY
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myeloid-Derived Suppressor Cells Accumulate in Kidney Allograft Tolerance and Specifically Suppress Effector T Cell Expansion
- (2014) A.-S. Dugast et al. JOURNAL OF IMMUNOLOGY
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)
- (2014) M. Donini et al. Targeted Oncology
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
- (2013) Nicola E. Annels et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- (2013) Y. Homma et al. Clinical & Translational Oncology
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
- (2013) Chandan Verma et al. Journal of Translational Medicine
- Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
- (2013) C. Lu-Emerson et al. NEURO-ONCOLOGY
- Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
- (2012) Eva Ellebaek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Modulation of Immunity by Antiangiogenic Molecules in Cancer
- (2012) Magali Terme et al. Clinical & Developmental Immunology
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
- (2012) John H. Sampson et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome
- (2012) BARBARA VIZIO et al. Experimental and Therapeutic Medicine
- Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
- (2012) Taku Fujimura et al. OncoImmunology
- Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
- (2011) D. A. Mitchell et al. BLOOD
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas
- (2011) Taku Fujimura et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
- (2011) C. E. Fadul et al. NEURO-ONCOLOGY
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- (2011) B. Raychaudhuri et al. NEURO-ONCOLOGY
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC
- (2010) Tim F. Greten et al. JOURNAL OF IMMUNOTHERAPY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
- (2009) Paulo C. Rodriguez et al. CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine
- (2009) H.-J. Ko et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
- (2008) A. B. Heimberger et al. CLINICAL CANCER RESEARCH
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-evolution of tumor cells and their microenvironment
- (2008) Kornelia Polyak et al. TRENDS IN GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started